Skip to content

Study · Animal study (in vivo) · rat · 1998

3 results

Effects of delta-sleep-inducing peptide in cerebral ischemia in rats.

Shandra AA, Godlevskii LS, Brusentsov AI, Vast'yanov RS, Karlyuga VA, Dzygal AF, Nikel B

Neuroscience and behavioral physiology1 Jul 1998Cited by 4 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bilateral cerebral ischemia, DSIP reduced the severity of postural abnormalities within 24 h.

    In plain wordsIn rats with reduced brain blood flow, DSIP lessened postural problems within 24 hours.

    Outcome
    DecreasePostural abnormalities after cerebral ischemia
    Study

    ratn: not reported in source

    bilateral carotid artery compression (cerebral ischemia)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These studies led to the conclusion that the peptide had pronounced anti-ischemic effects, which were evident within 24 h and consisted of reductions in the severity of postural abnormalities in rats with bilateral cerebral ischemia, along with a reduction in lethality.
    1 context sentence
    Summary · context
    Experimental studies were carried out to investigate the neuroprotective effects of delta sleep-inducing peptide in animals with cerebral ischemia induced by bilateral compression of both carotid arteries, and to compare the efficacy of this peptide with that of MK-801.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bilateral cerebral ischemia, DSIP reduced lethality.

    In plain wordsIn rats with reduced brain blood flow, DSIP lowered deaths.

    Outcome
    DecreaseLethality after cerebral ischemia
    Study

    ratn: not reported in source

    bilateral carotid artery compression (cerebral ischemia)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These studies led to the conclusion that the peptide had pronounced anti-ischemic effects, which were evident within 24 h and consisted of reductions in the severity of postural abnormalities in rats with bilateral cerebral ischemia, along with a reduction in lethality.
    1 context sentence
    Summary · context
    Experimental studies were carried out to investigate the neuroprotective effects of delta sleep-inducing peptide in animals with cerebral ischemia induced by bilateral compression of both carotid arteries, and to compare the efficacy of this peptide with that of MK-801.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with cerebral ischemia, DSIP had a greater neuroprotective effect than MK-801.

    In plain wordsIn rats with reduced brain blood flow, DSIP protected the brain more than MK-801 did.

    Outcome
    IncreaseNeuroprotective effect versus MK-801
    Study

    ratn: not reported in source

    bilateral carotid artery compression (cerebral ischemia)
    Comparator
    MK-801
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Comparison of the efficacies of peptide and MK-801 showed the peptide to have the greater neuroprotective effect.
    1 context sentence
    Summary · context
    Experimental studies were carried out to investigate the neuroprotective effects of delta sleep-inducing peptide in animals with cerebral ischemia induced by bilateral compression of both carotid arteries, and to compare the efficacy of this peptide with that of MK-801.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.